More Prescient Therapeutics Limited news
Prescient Therapeutics LimitedASX: PTX

Transgene TG4010 Exclusive Option

Feb 10, 2016 at 8:19 PM EST · Issued by Prescient Therapeutics Limited

Filed with ASX · Feb 10, 2016 at 8:19 PM EST · 5 pages · English and French

On 6ix: 6ix.com/news/transgene-tg4010-exclusive-option

Prescient Therapeutics Limited on 6ix

Later from Prescient Therapeutics

  • December 2015 Appendix 4C - QuarterlyFeb 11, 2016
  • Steven Yatomi-Clarke Appointed CEOFeb 15, 2016
  • PTX-200 Breast Cancer Trial ProgressesFeb 16, 2016
  • Approval received to transfer IND Sponsorship for PTX-200Mar 30, 2016
  • December 2014 Appendix 4C - quarterlyMar 30, 2016
All Prescient Therapeutics news releases↗

Follow Prescient Therapeutics into a list and get an email when it puts out news.

Follow Prescient Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer